Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAPR NASDAQ:INBX NASDAQ:TENX NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$22.43-3.4%$28.65$4.30▼$40.37$1.34B0.421.49 million shs2.13 million shsINBXInhibrx Biosciences$97.14-0.5%$104.90$15.82▼$155.29$1.43B3.41293,330 shs527,701 shsTENXTenax Therapeutics$16.26+5.2%$12.37$5.68▼$18.38$410.08M0.921.29 million shs1.52 million shsXERSXeris Biopharma$8.37+1.1%$6.65$4.62▼$10.08$1.43B0.622.10 million shs1.91 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics0.00%-12.22%-13.10%-26.74%+129.92%INBXInhibrx Biosciences0.00%+2.92%+12.15%+53.14%+499.20%TENXTenax Therapeutics0.00%+15.03%+44.08%+3.90%+159.40%XERSXeris Biopharma0.00%+7.67%+33.98%+36.86%+74.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$22.43-3.4%$28.65$4.30▼$40.37$1.34B0.421.49 million shs2.13 million shsINBXInhibrx Biosciences$97.14-0.5%$104.90$15.82▼$155.29$1.43B3.41293,330 shs527,701 shsTENXTenax Therapeutics$16.26+5.2%$12.37$5.68▼$18.38$410.08M0.921.29 million shs1.52 million shsXERSXeris Biopharma$8.37+1.1%$6.65$4.62▼$10.08$1.43B0.622.10 million shs1.91 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics0.00%-12.22%-13.10%-26.74%+129.92%INBXInhibrx Biosciences0.00%+2.92%+12.15%+53.14%+499.20%TENXTenax Therapeutics0.00%+15.03%+44.08%+3.90%+159.40%XERSXeris Biopharma0.00%+7.67%+33.98%+36.86%+74.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPRCapricor Therapeutics 2.90Moderate Buy$53.67139.26% UpsideINBXInhibrx Biosciences 2.33Hold$150.0054.42% UpsideTENXTenax Therapeutics 2.86Moderate Buy$38.00133.70% UpsideXERSXeris Biopharma 2.43Hold$10.8029.03% UpsideCurrent Analyst Ratings BreakdownLatest TENX, INBX, CAPR, and XERS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026TENXTenax Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.006/30/2026TENXTenax Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/25/2026CAPRCapricor Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2026TENXTenax Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$35.006/22/2026TENXTenax Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.00 ➝ $40.006/22/2026TENXTenax Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.006/16/2026INBXInhibrx Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/15/2026CAPRCapricor Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/12/2026TENXTenax Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $50.006/1/2026TENXTenax Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/15/2026CAPRCapricor Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.00(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPRCapricor Therapeutics$22.27M58.33N/AN/A$5.53 per share4.06INBXInhibrx Biosciences$1.30M1,096.19N/AN/A$0.55 per share176.62TENXTenax TherapeuticsN/AN/AN/AN/A$10.42 per shareN/AXERSXeris Biopharma$291.85M4.95$0.10 per share82.66$0.08 per share104.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPRCapricor Therapeutics-$105.04M-$2.32N/AN/AN/AN/A-59.27%-48.65%8/11/2026 (Estimated)INBXInhibrx Biosciences-$140.05M-$8.39N/AN/AN/AN/A-563.90%-72.32%8/12/2026 (Estimated)TENXTenax Therapeutics-$52.60M-$1.40N/AN/AN/AN/A-56.32%-53.12%8/12/2026 (Estimated)XERSXeris Biopharma$550K$0.06139.5025.36N/A3.81%735.00%3.24%8/6/2026 (Estimated)Latest TENX, INBX, CAPR, and XERS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026INBXInhibrx Biosciences-$1.6750-$2.15-$0.4750-$2.15N/AN/A5/12/2026Q1 2026CAPRCapricor Therapeutics-$0.55-$0.59-$0.04-$0.59$40.00 millionN/A5/12/2026Q1 2026TENXTenax Therapeutics-$0.40-$0.35+$0.05-$0.35N/AN/A5/7/2026Q1 2026XERSXeris Biopharma-$0.0027$0.01+$0.0127$0.01$79.83 million$83.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCAPRCapricor TherapeuticsN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPRCapricor TherapeuticsN/A8.428.42INBXInhibrx Biosciences12.586.466.46TENXTenax TherapeuticsN/A14.5214.52XERSXeris Biopharma17.002.121.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPRCapricor Therapeutics21.68%INBXInhibrx Biosciences82.46%TENXTenax Therapeutics1.67%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipCAPRCapricor Therapeutics9.20%INBXInhibrx Biosciences18.26%TENXTenax Therapeutics3.70%XERSXeris Biopharma4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAPRCapricor Therapeutics10157.91 million52.58 millionOptionableINBXInhibrx Biosciences16614.67 million11.99 millionOptionableTENXTenax Therapeutics926.52 million25.54 millionNot OptionableXERSXeris Biopharma290172.64 million165.13 millionOptionableTENX, INBX, CAPR, and XERS HeadlinesRecent News About These CompaniesXeris Biopharma (NASDAQ:XERS) Insider Sells $722,700.00 in StockJuly 5 at 6:06 AM | americanbankingnews.comInsider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $133,827.98 in StockJuly 5 at 5:29 AM | americanbankingnews.comBeth Hecht Sells 16,666 Shares of Xeris Biopharma (NASDAQ:XERS) StockJuly 3 at 6:36 AM | insidertrades.comCORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 2, 2026 | businesswire.comXeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 2, 2026 | businesswire.comXeris Announces Updates to Its Board of DirectorsJune 30, 2026 | finance.yahoo.comIs Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?June 30, 2026 | finance.yahoo.comReviewing Aptorum Group (NASDAQ:APM) and Xeris Biopharma (NASDAQ:XERS)June 30, 2026 | americanbankingnews.comComparing Xeris Biopharma (NASDAQ:XERS) & Carisma Therapeutics (NASDAQ:CARM)June 28, 2026 | americanbankingnews.comIshara Investments LP Buys New Holdings in Xeris Biopharma Holdings, Inc. $XERSJune 18, 2026 | marketbeat.comXeris Biopharma Holdings, Inc. $XERS Stock Position Raised by Granahan Investment Management LLCJune 17, 2026 | marketbeat.comJim Cramer Blesses a Caller’s Speculative Investment in Xeris BiopharmaJune 12, 2026 | insidermonkey.comXeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®June 11, 2026 | businesswire.comXeris to retire $23M of convertible notes through exchange agreementsJune 11, 2026 | seekingalpha.comXeris Biopharma Announces Private Exchange of Convertible NotesJune 11, 2026 | finance.yahoo.comXeris Biopharma Announces Debt Reduction via Note ExchangesJune 11, 2026 | tipranks.comXeris Biopharma (NASDAQ:XERS) Director Sells $91,350.00 in StockJune 6, 2026 | insidertrades.comXeris Biopharma Shareholders Elect Directors and Ratify AuditorJune 5, 2026 | tipranks.comXeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 SharesJune 3, 2026 | insidertrades.comXeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway RightMay 30, 2026 | seekingalpha.comShareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) EarningsMay 15, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026Capri's Turnaround Is Taking Shape, But Is the Stock a Buy Yet?By Jennifer Ryan Woods | June 28, 2026TENX, INBX, CAPR, and XERS Company DescriptionsCapricor Therapeutics NASDAQ:CAPR$22.43 -0.78 (-3.36%) Closing price 04:00 PM EasternExtended Trading$22.53 +0.10 (+0.45%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Inhibrx Biosciences NASDAQ:INBX$97.14 -0.44 (-0.45%) Closing price 04:00 PM EasternExtended Trading$100.93 +3.79 (+3.90%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Tenax Therapeutics NASDAQ:TENX$16.26 +0.80 (+5.17%) Closing price 04:00 PM EasternExtended Trading$16.29 +0.03 (+0.16%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.Xeris Biopharma NASDAQ:XERS$8.37 +0.09 (+1.09%) Closing price 04:00 PM EasternExtended Trading$8.40 +0.03 (+0.36%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
